Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole fMRI in MDD with Anxiety
NCT05504486Phase 4Withdrawn
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Aug 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of brexpiprazole orally disintegrating tablet in major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Planned start Aug 2022; status: withdrawn.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05504486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504486.